Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: A randomized, double-blind, 6-month study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 7, 2014, Pages 613-621

  Pratley, R E ^a   Fleck, P ^b   Wilson, C ^b  

^a FLORIDA HOSPITAL   (United States)

^b TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

Author keywords

Alogliptin; Coadministration; Combination therapy; Dipeptidyl peptidase 4 inhibitor; DPP 4; Metformin; Monotherapy; T2DM; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; AMYLASE; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; URACIL;

ABDOMINAL DISTENSION; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLAMMATION; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PANCREATITIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SILENT MYOCARDIAL INFARCTION; SKIN MANIFESTATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME; URACIL;

EID: 84903187359     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12258     Document Type: Article

References (23)

1. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach; position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2009; 32: 193-203.
3. The National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: The Management of Type 2 Diabetes. NICE Clinical Guideline 87. Royal College of Physicians, London, 2009. Available from URL: http://www.nice.org.uk/ nicemedia/pdf/CG87NICEGuideline.pdf. Accessed 25 January 2014.
4. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2012. Available from URL: http://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed 25 January 2014.
5. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506-515.
6. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
7. Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011; 4: 263-271.
8. Forst T, Uhlig-Laske B, Ring A et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010; 27: 1409-1419.
9. Goke B, Gallwitz B, Erikkson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomized controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
10. Jadzinsky M, Pfutzner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
11. Raz I, Chen Y, Wu M et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-550.
12. Scheen AJ. Metformin+saxagliptin for type 2 diabetes. Exp Opin Pharmacother 2012; 13: 139-146.
13. Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959-969.
14. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583.
15. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin. Vasc Health Risk Manag 2008; 4: 383-394.
16. Migoya EM, Bergeron R, Miller JL et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-808.
17. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011; 54: 339-349.
18. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219-222.
19. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46-55.
20. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503-512.
21. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63: 1879-1894.
22. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008; 588(2-3): 325-332.
23. Metformin 500 mg tablets. 2008. Summary of Product Characteristics. Teva UK Limited, Eastbourne, UK.